Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision.
Language barrier, race, immigration status, mental health illness, substance abuse and socioeconomic status are often not considered when evaluating hepatitis C virus (HCV) sustained virological response (SVR) in human immunodeficiency virus (HIV) infection. The influence of these factors on HCV work-up, treatment initiation and SVR were assessed in an HIV-HCV coinfected population and compared to patients with HCV mono-infection. The setting was a publicly funded, urban-based, multidisciplinary viral hepatitis clinic. A clinical database was utilized to identify HIV and HCV consults between June 2000 and June 2007. Measures of access to HCV care (ie, liver biopsy and HCV antiviral initiation) and SVR as a function of the above variables were evaluated and compared between patients with HIV-HCV and HCV. HIV-HCV co-infected (n = 106) and HCV mono-infected (n = 802) patients were evaluated. HIV-HCV patients were more often white (94% versus 84%) and male (87% versus 69%). Bridging fibrosis or cirrhosis on biopsy was more frequent in HIV-HCV (37% versus 22%; P = 0.03). HIV infection itself did not influence access to biopsy (50% versus 52%) or treatment initiation (39% versus 38%). Race, language barrier, immigration status, injection drug history and socioeconomic status did not influence access to biopsy or treatment. SVR was 54% in HCV and 30% in HIV-HCV (P = 0.003). Genotype and HIV were the only evaluated variables to predict SVR. Within the context of a socialized, multidisciplinary clinic, HIV-HCV co-infected patients received similar access to HCV work-up and care as HCV mono-infected patients. SVR is diminished in HIV-HCV co-infection independent of language barrier, race, immigration status, or socioeconomic status.
Cooper
Curtis L
CL
The University of Ottawa Division of Infectious Diseases Viral Hepatitis Program, Ottawa, Canada.
Giordano
Celine
C
Mackie
Dave
D
Mills
Edward J
EJ
J Psychosom Res. 2000 Nov;49(5):311-7
11164055
Clin Infect Dis. 2003 Jan 1;36(1):97-100
12491208
Health Serv Res. 2003 Jun;38(3):789-808
12822913
Clin Infect Dis. 2002 Apr 1;34(7):984-90
11880965
J Viral Hepat. 2007 Mar;14(3):183-8
17305884
AIDS. 2005 Oct;19 Suppl 3:S208-14
16251820
Gut. 2007 Mar;56(3):385-9
17005764
N Engl J Med. 2004 Jul 29;351(5):438-50
15282351
Lancet. 2001 Sep 22;358(9286):958-65
11583749
J Infect Dis. 1999 May;179(5):1254-8
10191232
Hepatology. 1999 Oct;30(4):1054-8
10498659
J Subst Abuse Treat. 2002 Oct;23(3):225-30
12392809
CMAJ. 2001 Sep 4;165(5):565-70
11563208
Harm Reduct J. 2006 Nov 10;3:31
17096852
J Gen Intern Med. 2005 Nov;20(11):1050-6
16307633
Soc Sci Med. 2000 Jul;51(1):123-33
10817475
Health Rep. 2007 Feb;18(1):23-35
17441441
JAMA. 2004 Dec 15;292(23):2839-48
15598915
J Am Acad Dermatol. 2006 Feb;54(2):331-5
16443069
Can J Gastroenterol. 2006 Feb;20(2):81-6
16482232
Psychiatr Serv. 2006 Mar;57(3):317-24
16524988
J Gen Intern Med. 2001 Jul;16(7):468-74
11520385
J Viral Hepat. 2005 Jan;12(1):86-90
15655053
N Engl J Med. 2002 Sep 26;347(13):975-82
12324553
Milbank Q. 2006;84(1):111-33
16529570
Eur J Gastroenterol Hepatol. 2009 Feb;21(2):131-6
19092675
World J Gastroenterol. 2007 Feb 21;13(7):1074-8
17373742
AIDS. 2008 Aug;22 Suppl 2:S67-79
18641472